1.43

1.42% 0.02

After Hours: 1.43

Repare Therapeutics Inc (RPTX)

Overview News Price History Option Chain Financials Discussions Forecast

Repare Therapeutics Inc stock is traded at $1.43, with a volume of 264.17K. It is up +1.42% in the last 24 hours and up +33.64% over the past month. Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Previous Close:

$1.41

Open:

$1.41

24h Volume:

264.17K

Relative Volume:

0.88

Market Cap:

$53.14M

Revenue:

$51.13M

Net Income/Loss:

$-93.80M

P/E Ratio:

-0.6413

EPS:

-2.23

Net Cash Flow:

$-129.10M

1W Performance:

+14.40%

1M Performance:

+33.64%

6M Performance:

-60.06%

1Y Performance:

-57.31%

1-Day Range:

$1.40

$1.48

1-Week Range:

$1.2601

$1.48

52-Week Range:

$0.89

$4.29

Repare Therapeutics Inc Stock (RPTX) Company Profile

Name

Repare Therapeutics Inc

Sector

Healthcare (1152)

Industry

Biotechnology (677)

Phone

(857) 412-7018

Address

7171 FREDERICK BANTING, SAINT-LAURENT, QC

Employee

129

Twitter

@reparerx

Next Earnings Date

2023-08-09

Latest SEC Filings

RPTX's Discussions on Twitter

Compare RPTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPTX Repare Therapeutics Inc	1.43	53.14M	51.13M	-93.80M	-129.10M	-2.23
VRTX Vertex Pharmaceuticals Inc	501.15	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	605.61	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	649.67	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	259.39	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	255.77	26.40B	3.81B	-644.79M	-669.77M	-6.24

Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-09-23	Upgrade	Stifel	Hold → Buy
Feb-03-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-06-23	Initiated	CapitalOne	Overweight
Apr-12-22	Downgrade	Stifel	Buy → Hold
Mar-17-22	Resumed	Goldman	Buy
Sep-23-21	Initiated	Stifel	Buy
Sep-13-21	Initiated	H.C. Wainwright	Buy
Jun-28-21	Initiated	Guggenheim	Buy
Mar-01-21	Initiated	Berenberg	Buy
Oct-28-20	Initiated	Northland Capital	Outperform
Jul-14-20	Initiated	Cowen	Outperform
Jul-14-20	Initiated	Goldman	Neutral
Jul-14-20	Initiated	Morgan Stanley	Overweight
Jul-14-20	Initiated	Piper Sandler	Overweight

View All

Repare Therapeutics Inc Stock (RPTX) Latest News

04:27 AM

Repare signs out-licensing deal with DCx Biotherapeutics - Yahoo Finance

04:27 AM

May 01, 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - CRISPR Medicine News

May 01, 2025

Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News

May 01, 2025

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - BioSpace

May 01, 2025

Apr 29, 2025

Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Apr 29, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 25, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Drop in Short Interest - MarketBeat

Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - CRISPR Medicine News

Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Present - GuruFocus

Apr 25, 2025

Apr 24, 2025

Do investors need to be concerned about Repare Therapeutics Inc (RPTX)? - uspostnews.com

Apr 24, 2025

Insider’s View: Deciphering Repare Therapeutics Inc (RPTX)’s Financial Health Through Ratios - DWinneX

Apr 24, 2025

Apr 23, 2025